Recent Weight Loss

Free Symptom Checker
with Physician-supervised AI

Worried about your symptoms?

Start the Recent Weight Loss test with our free AI Symptom Checker.

This will help us personalize your assessment.

Shiba

By starting the symptom checker, you agree to the Privacy Policy and Terms of Use

Try one of these related symptoms.

Lost weight recently

Losing too much weight

Became slender

About the Symptom

It refers to a recent noticeable drop in body weight that occurs.

When to See a Doctor

Seek professional care if you experience any of the following symptoms

Possible Causes

Generally, Recent weight loss can be related to:

Related Serious Diseases

Sometimes, Recent weight loss may be related to these serious diseases:

Doctor's Diagnostic Questions

Your doctor may ask these questions to check for this symptom:

Reviewed By:

Unnati Patel, MD, MSc

Unnati Patel, MD, MSc (Family Medicine)

Dr.Patel serves as Center Medical Director and a Primary Care Physician at Oak Street Health in Arizona. She graduated from the Zhejiang University School of Medicine prior to working in clinical research focused on preventive medicine at the University of Illinois and the University of Nevada. Dr. Patel earned her MSc in Global Health from Georgetown University, during which she worked with the WHO in Sierra Leone and Save the Children in Washington, D.C. She went on to complete her Family Medicine residency in Chicago at Norwegian American Hospital before completing a fellowship in Leadership in Value-based Care in conjunction with the Northwestern University Kellogg School of Management, where she earned her MBA. Dr. Patel’s interests include health tech and teaching medical students and she currently serves as Clinical Associate Professor at the University of Arizona School of Medicine.

Yoshinori Abe, MD

Yoshinori Abe, MD (Internal Medicine)

Dr. Abe graduated from The University of Tokyo School of Medicine in 2015. He completed his residency at the Tokyo Metropolitan Health and Longevity Medical Center. He co-founded Ubie, Inc. in May 2017, where he currently serves as CEO & product owner at Ubie. Since December 2019, he has been a member of the Special Committee for Activation of Research in Emergency AI of the Japanese Association for Acute Medicine. | | Dr. Abe has been elected in the 2020 Forbes 30 Under 30 Asia Healthcare & Science category.

From our team of 50+ doctors

Content updated on Jul 16, 2025

Following the Medical Content Editorial Policy

Was this page helpful?

Tell your friends about us.

We would love to help them too.

smily Shiba-inu looking

Just 3 minutes.
Developed by doctors.

Try Free Symptom Quiz

How Ubie Can Help You

With a free 3-min Recent Weight Loss quiz, powered by Ubie's AI and doctors, find possible causes of your symptoms.

This questionnaire is customized to your situation and symptoms, including the following personal information:

  • Biological Sex - helps us provide relevant suggestions for male vs. female conditions.

  • Age - adjusts our guidance based on any age-related health factors.

  • History - considers past illnesses, surgeries, family history, and lifestyle choices.

Your symptoms

Input your symptoms

Our AI

Our AI checks your symptoms

Your report

You get your personalized report

Your personal report will tell you

✔  When to see a doctor

✔︎  What causes your symptoms

✔︎  Treatment information etc.

People with similar symptoms also use Ubie's symptom checker to find possible causes

Find Similar Symptoms

FAQs

Q.

Are patients worried about muscle loss from GLP-1 agonists?

A.

Some patients are concerned about muscle loss when using GLP-1 agonists, but studies show mixed results on this issue.

References:

Neeland IJ, Linge J, & Birkenfeld AL. (2024). Changes in lean body mass with glucagon-like peptide-1- .... Diabetes, obesity & metabolism, 38937282.

https://pubmed.ncbi.nlm.nih.gov/38937282/

Memel Z, Gold SL, Pearlman M, Muratore A, & Martindale R. (2025). Impact of GLP- 1 Receptor Agonist Therapy in Patients .... Current nutrition reports, 40289060.

https://pubmed.ncbi.nlm.nih.gov/40289060/

Linge J, Birkenfeld AL, & Neeland IJ. (2024). Muscle Mass and Glucagon-Like Peptide-1 Receptor .... Circulation, 39401279.

https://pubmed.ncbi.nlm.nih.gov/39401279/

See more on Doctor's Note

Q.

Are seniors more prone to muscle loss on GLP-1s?

A.

Seniors taking GLP-1 medications may be more likely to experience muscle loss, especially with drugs like semaglutide.

References:

Neeland IJ, Linge J, & Birkenfeld AL. (2024). Changes in lean body mass with glucagon-like peptide-1- .... Diabetes, obesity & metabolism, 38937282.

https://pubmed.ncbi.nlm.nih.gov/38937282/

Linge J, Birkenfeld AL, & Neeland IJ. (2024). Muscle Mass and Glucagon-Like Peptide-1 Receptor .... Circulation, 39401279.

https://pubmed.ncbi.nlm.nih.gov/39401279/

Ren Q, Zhi L, & Liu H. (2025). Semaglutide Therapy and Accelerated Sarcopenia in Older .... Drug design, development and therapy, 40631351.

https://pubmed.ncbi.nlm.nih.gov/40631351/

See more on Doctor's Note

Q.

Can GLP-1 drugs affect physical function due to muscle loss?

A.

GLP-1 drugs can lead to muscle loss, which may affect physical function, but there are strategies to minimize this risk.

References:

Neeland IJ, Linge J, & Birkenfeld AL. (2024). Changes in lean body mass with glucagon-like peptide-1- .... Diabetes, obesity & metabolism, 38937282.

https://pubmed.ncbi.nlm.nih.gov/38937282/

Mechanick JI, Butsch WS, Christensen SM, Hamdy O, Li Z, Prado CM, & Heymsfield SB. (2025). Strategies for minimizing muscle loss during use of incretin .... Obesity reviews : an official journal of the International Association for the Study of Obesity, 39295512.

https://pubmed.ncbi.nlm.nih.gov/39295512/

Abbatecola AM, Olivieri F, Corsonello A, Strollo F, Fumagalli A, & Lattanzio F. (2012). Frailty and safety: the example of diabetes. Drug safety, 23446787.

https://pubmed.ncbi.nlm.nih.gov/23446787/

See more on Doctor's Note

Q.

How can diet prevent muscle loss on GLP-1s?

A.

Eating more protein can help keep muscles strong while using GLP-1 medications.

References:

Moon J, & Koh G. (2020). Clinical Evidence and Mechanisms of High-Protein Diet .... Journal of obesity & metabolic syndrome, 32699189.

https://pubmed.ncbi.nlm.nih.gov/32699189/

Neeland IJ, Linge J, & Birkenfeld AL. (2024). Changes in lean body mass with glucagon-like peptide-1- .... Diabetes, obesity & metabolism, 38937282.

https://pubmed.ncbi.nlm.nih.gov/38937282/

Mechanick JI, Butsch WS, Christensen SM, Hamdy O, Li Z, Prado CM, & Heymsfield SB. (2025). Strategies for minimizing muscle loss during use of incretin .... Obesity reviews : an official journal of the International Association for the Study of Obesity, 39295512.

https://pubmed.ncbi.nlm.nih.gov/39295512/

See more on Doctor's Note

Q.

How does enobosarm compare to placebo for lean mass preservation?

A.

Enobosarm has been shown to help preserve lean body mass better than a placebo in clinical trials.

References:

Dobs AS, Boccia RV, Croot CC, Gabrail NY, Dalton JT, Hancock ML, et al. (2013). a double-blind, randomised controlled phase 2 trial. The Lancet. Oncology, 23499390.

https://pubmed.ncbi.nlm.nih.gov/23499390/

Crawford J, Prado CM, Johnston MA, Gralla RJ, Taylor RP, Hancock ML, & Dalton JT. (2016). Study Design and Rationale for the Phase 3 Clinical .... Current oncology reports, 27138015.

https://pubmed.ncbi.nlm.nih.gov/27138015/

Neil D, Clark RV, Magee M, Billiard J, Chan A, Xue Z, & Russell A. (2018). GSK2881078, a SARM, Produces Dose-Dependent .... The Journal of clinical endocrinology and metabolism, 29982690.

https://pubmed.ncbi.nlm.nih.gov/29982690/

See more on Doctor's Note

Q.

How does enobosarm work to preserve lean mass?

A.

Enobosarm helps keep muscles strong by acting like hormones that build muscle, without some of the bad side effects.

References:

Leciejewska N, Kołodziejski PA, Sassek M, Nogowski L, Małek E, & Pruszyńska-Oszmałek E. (2022). Ostarine-Induced Myogenic Differentiation in C2C12, L6, .... International journal of molecular sciences, 35457222.

https://pubmed.ncbi.nlm.nih.gov/35457222/

Taoussi O, Bambagiotti G, Gameli PS, Daziani G, Tavoletta F, Tini A, et al. (2024). In Vitro and In Vivo Human Metabolism of Ostarine, a .... International journal of molecular sciences, 39063049.

https://pubmed.ncbi.nlm.nih.gov/39063049/

Dutt V, Gupta S, Dabur R, Injeti E, & Mittal A. (2015). Skeletal muscle atrophy: Potential therapeutic agents and .... Pharmacological research, 26048279.

https://pubmed.ncbi.nlm.nih.gov/26048279/

See more on Doctor's Note

Q.

How prevalent is muscle loss among GLP-1 users?

A.

Muscle loss can occur in people using GLP-1 medications like semaglutide, especially if they lose weight quickly without exercise.

References:

Neeland IJ, Linge J, & Birkenfeld AL. (2024). Changes in lean body mass with glucagon-like peptide-1- .... Diabetes, obesity & metabolism, 38937282.

https://pubmed.ncbi.nlm.nih.gov/38937282/

Bikou A, Dermiki-Gkana F, Penteris M, Constantinides TK, & Kontogiorgis C. (2024). A systematic review of the effect of semaglutide on lean mass. Expert opinion on pharmacotherapy, 38629387.

https://pubmed.ncbi.nlm.nih.gov/38629387/

Grosicki GJ, Dhurandhar NV, Unick JL, Arent SM, Thomas JG, Lofton H, et al. (2024). The Importance of Diet and Physical Activity to Support .... Current developments in nutrition, 39624804.

https://pubmed.ncbi.nlm.nih.gov/39624804

See more on Doctor's Note

Q.

Is muscle loss a known side effect of GLP-1 drugs?

A.

GLP-1 drugs can lead to a decrease in muscle mass, which is a side effect to consider.

References:

Neeland IJ, Linge J, & Birkenfeld AL. (2024). Changes in lean body mass with glucagon-like peptide-1- .... Diabetes, obesity & metabolism, 38937282.

https://pubmed.ncbi.nlm.nih.gov/38937282/

Old VJ, Davies MJ, Papamargaritis D, Choudhary P, & Watson EL. (2025). The Effects of Glucagon-Like Peptide-1 Receptor Agonists .... Journal of cachexia, sarcopenia and muscle, 39815782.

https://pubmed.ncbi.nlm.nih.gov/39815782/

Linge J, Birkenfeld AL, & Neeland IJ. (2024). Muscle Mass and Glucagon-Like Peptide-1 Receptor .... Circulation, 39401279.

https://pubmed.ncbi.nlm.nih.gov/39401279/

See more on Doctor's Note

Q.

Is there a way to mitigate muscle loss from GLP-1 medications?

A.

To reduce muscle loss from GLP-1 medications, it's important to focus on good nutrition and regular exercise. Eating enough protein and doing strength exercises can help keep muscles strong.

References:

Mechanick JI, Butsch WS, Christensen SM, Hamdy O, Li Z, Prado CM, & Heymsfield SB. (2025). Strategies for minimizing muscle loss during use of incretin .... Obesity reviews : an official journal of the International Association for the Study of Obesity, 39295512.

https://pubmed.ncbi.nlm.nih.gov/39295512/

Chavez AM, Carrasco Barria R, & León-Sanz M. (2025). Nutrition support whilst on glucagon-like peptide-1 based .... Current opinion in clinical nutrition and metabolic care, 40401903.

https://pubmed.ncbi.nlm.nih.gov/40401903/

Caturano A, Amaro A, Berra CC, & Conte C. (2025). Sarcopenic obesity and weight loss-induced muscle mass .... Current opinion in clinical nutrition and metabolic care, 40296814.

https://pubmed.ncbi.nlm.nih.gov/40296814/

See more on Doctor's Note

Q.

Should I ask my doctor about GLP-1 and muscle loss?

A.

Yes, you should talk to your doctor about GLP-1 medications and muscle loss, as some studies suggest they might affect muscles.

References:

Sforzo GA, Gordon NF, Peeke PM, & Moore M. (2024). Health and Well-Being Coaching Adjuvant to GLP-1 .... American Journal of Lifestyle Medicine, 11577329.

https://pmc.ncbi.nlm.nih.gov/articles/PMC11577329/

Billings SA, Felix HM, Prier CC, & Hedges MS. (2023). Rhabdomyolysis Associated With Semaglutide Therapy. Cureus, 10773591.

https://pmc.ncbi.nlm.nih.gov/articles/PMC10773591/

Ma XY, & Chen FQ. (2021). Effects of anti-diabetic drugs on sarcopenia: Best treatment .... World Journal of Clinical Cases, 8638038.

https://pmc.ncbi.nlm.nih.gov/articles/PMC8638038/

See more on Doctor's Note

Q.

What are the signs of muscle weakness from GLP-1 drugs?

A.

GLP-1 drugs like semaglutide can sometimes cause muscle weakness, which may be due to conditions like rhabdomyolysis. However, they may also help with certain muscle problems.

References:

Brand K, Landry D, Mulhern J, & Braden G. (2025). Semaglutide reverses the chronic myopathy of .... BMC nephrology, 40197299.

https://pubmed.ncbi.nlm.nih.gov/40197299/

Billings SA, Felix HM, Prier CC, & Hedges MS. (2023). Rhabdomyolysis Associated With Semaglutide Therapy. Cureus, 38192938.

https://pubmed.ncbi.nlm.nih.gov/38192938/

Ditzenberger GL, Lake JE, Kitch DW, Kantor A, Muthupillai R, Moser C, et al. (2025). Effects of Semaglutide on Muscle Structure and Function in .... Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 39046173.

https://pubmed.ncbi.nlm.nih.gov/39046173/

See more on Doctor's Note

Q.

What is the FDA status of enobosarm for obesity treatment?

A.

Enobosarm is not currently approved by the FDA for treating obesity.

References:

Crawford J, Prado CM, Johnston MA, Gralla RJ, Taylor RP, Hancock ML, & Dalton JT. (2016). Study Design and Rationale for the Phase 3 Clinical .... Current Oncology Reports, 4853438.

https://pmc.ncbi.nlm.nih.gov/articles/PMC4853438/

Christiansen AR, Lipshultz LI, Hotaling JM, & Pastuszak AW. (2020). Selective androgen receptor modulators: the future of .... Translational Andrology and Urology, 7108998.

https://pmc.ncbi.nlm.nih.gov/articles/PMC7108998/

Weinblatt D, & Roy S. (2022). Drug-Induced Liver Injury Secondary to Enobosarm. Journal of Medical Cases, 9119364.

https://pmc.ncbi.nlm.nih.gov/articles/PMC9119364/

See more on Doctor's Note

Q.

What is the role of protein in maintaining muscle on GLP-1s?

A.

Protein helps keep muscles strong when using GLP-1 medications by providing essential nutrients. Eating enough protein is important to prevent muscle loss.

References:

Chavez AM, Carrasco Barria R, & León-Sanz M. (2025). Nutrition support whilst on glucagon-like peptide-1 based .... Current opinion in clinical nutrition and metabolic care, 40401903.

https://pubmed.ncbi.nlm.nih.gov/40401903/

Mechanick JI, Butsch WS, Christensen SM, Hamdy O, Li Z, Prado CM, & Heymsfield SB. (2025). Strategies for minimizing muscle loss during use of incretin .... Obesity reviews : an official journal of the International Association for the Study of Obesity, 39295512.

https://pubmed.ncbi.nlm.nih.gov/39295512/

Cannavaro D, Leva F, Caturano A, Berra CC, Bonfrate L, & Conte C. (2025). Optimizing Body Composition During Weight Loss. Nutrients, 40573110.

https://pubmed.ncbi.nlm.nih.gov/40573110/

See more on Doctor's Note

Q.

What percentage of GLP-1 users experience muscle loss?

A.

Some people using GLP-1 medications may experience muscle loss, but the exact percentage is not clear.

References:

Neeland IJ, Linge J, & Birkenfeld AL. (2024). Changes in lean body mass with glucagon-like peptide-1- .... Diabetes, obesity & metabolism, 38937282.

https://pubmed.ncbi.nlm.nih.gov/38937282/

Dubin RL, Heymsfield SB, Ravussin E, & Greenway FL. (2024). Glucagon-like peptide-1 receptor agonist-based agents .... Diabetes, obesity & metabolism, 39344838.

https://pubmed.ncbi.nlm.nih.gov/39344838/

Bikou A, Dermiki-Gkana F, Penteris M, Constantinides TK, & Kontogiorgis C. (2024). A systematic review of the effect of semaglutide on lean mass. Expert opinion on pharmacotherapy, 38629387.

https://pubmed.ncbi.nlm.nih.gov/38629387/

See more on Doctor's Note

Q.

What type of exercise helps with GLP-1 muscle wasting?

A.

To help with muscle loss from GLP-1 medications, doing resistance exercises like lifting weights can be beneficial.

References:

Locatelli JC, Costa JG, Haynes A, Naylor LH, Fegan PG, Yeap BB, & Green DJ. (2024). Incretin-Based Weight Loss Pharmacotherapy. Diabetes care, 38687506.

https://pubmed.ncbi.nlm.nih.gov/38687506/

Mechanick JI, Butsch WS, Christensen SM, Hamdy O, Li Z, Prado CM, & Heymsfield SB. (2025). Strategies for minimizing muscle loss during use of incretin .... Obesity reviews : an official journal of the International Association for the Study of Obesity, 39295512.

https://pubmed.ncbi.nlm.nih.gov/39295512/

Grosicki GJ, Dhurandhar NV, Unick JL, Arent SM, Thomas JG, Lofton H, et al. (2024). The Importance of Diet and Physical Activity to Support .... Current developments in nutrition, 39624804.

https://pubmed.ncbi.nlm.nih.gov/39624804

See more on Doctor's Note

Ubie is supervised by 50+ medical experts worldwide

Our symptom checker AI is continuously refined with input from experienced physicians, empowering them to make more accurate diagnoses.

Maxwell J. Nanes, DO

Maxwell J. Nanes, DO

Emergency Medicine

Waukesha Memorial Hospital, Waukesha Wisconsin, USA

Caroline M. Doan, DO

Caroline M. Doan, DO

Internal Medicine

Signify Health

Benjamin Kummer, MD

Benjamin Kummer, MD

Neurology, Clinical Informatics

Icahn School of Medicine at Mount Sinai

Charles Carlson, DO, MS

Charles Carlson, DO, MS

Psychiatry

U.S. Department of Veterans Affairs

Dale Mueller, MD

Dale Mueller, MD

Cardiothoracic and Vascular Surgery

Cardiothoracic and Vascular Surgery Associates

Ravi P. Chokshi, MD

Ravi P. Chokshi, MD

Obstetrics and gynecology

Penn State Health

Ubie is recognized by healthcare and tech leaders

Newsweek 2024

“World’s Best Digital
Health Companies”

Newsweek 2024

Google Play Best of 2023

“Best With AI”

Google Play Best of 2023

Digital Health Awards 2023

“Best in Class”

Digital Health Awards 2023 (Quarterfinalist)

Which is the best Symptom Checker?

Which is the best Symptom Checker?

Ubie’s symptom checker demonstrated a Top-10 hit accuracy of 71.6%, surpassing the performance of several leading symptom checkers in the market, which averaged around 60% accuracy in similar assessments.

Link to full study:

https://www.medrxiv.org/content/10.1101/2024.08.29.24312810v1